| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CCL8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CCL8抗体的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**: *CCL8 in breast cancer: Molecular mechanisms and therapeutic implications*
**作者**: Smith A, et al.
**摘要**: 该研究探讨了CCL8在乳腺癌微环境中的作用，发现使用抗CCL8中和抗体可显著抑制肿瘤相关巨噬细胞(TAMs)的募集，从而减缓肿瘤生长和转移。
2. **文献名称**: *Targeting CCL8 signaling to alleviate neuroinflammation in Alzheimer's disease models*
**作者**: Lee J, et al.
**摘要**: 研究通过阻断CCL8与其受体CCR5的相互作用(使用抗CCL8单克隆抗体)，发现可减少小胶质细胞激活和β-淀粉样蛋白沉积，改善阿尔茨海默病模型小鼠的认知功能。
3. **文献名称**: *CCL8 neutralization attenuates sepsis-induced acute lung injury via inhibition of neutrophil infiltration*
**作者**: Chen H, et al.
**摘要**: 实验表明，抗CCL8抗体能有效减少脓毒症模型中的中性粒细胞浸润和促炎因子释放，降低肺组织损伤程度，提示其作为脓毒症辅助治疗的潜力。
---
注：以上文献为虚拟示例，实际研究中建议通过PubMed或Web of Science检索具体文献。
CCL8 (C-C motif chemokine ligand 8), also known as monocyte chemoattractant protein-2 (MCP-2), is a small secreted protein belonging to the CC chemokine family. It binds to receptors such as CCR1. CCR2. CCR3. and CCR5. playing a key role in recruiting immune cells like monocytes, eosinophils, and T lymphocytes during inflammatory responses. CCL8 is implicated in chronic inflammation, autoimmune disorders, viral infections (e.g., HIV), and cancer progression. In cancer, it can promote tumor growth, angiogenesis, and metastasis by modulating the tumor microenvironment.
CCL8 antibodies are tools designed to detect, quantify, or neutralize CCL8 activity. They are widely used in research to study CCL8 expression patterns (via ELISA, Western blot, or immunohistochemistry) and its functional roles in disease models. Neutralizing antibodies, in particular, help dissect CCL8-mediated signaling pathways or evaluate its therapeutic targeting potential. Dysregulation of CCL8 has been observed in conditions like rheumatoid arthritis, multiple sclerosis, and breast cancer, making these antibodies valuable for both mechanistic studies and drug development. Their applications extend to preclinical investigations aiming to block CCL8-driven immune evasion or inflammation in pathological contexts.
×
